Physician profile
Himani Chandra
NPI 1801054697
$44,738.23
in general payments reported to CMS, 2019-2025
40 companies · $4,022 in 2025
The $4,022 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,138 · 2020: $6,569 · 2021: $3,849 · 2022: $4,628 · 2023: $8,594 · 2024: $11K · 2025: $4,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $2,684 · Travel and Lodging: $518 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,312.50 |
| Food and Beverage | $2,683.62 |
| Travel and Lodging | $517.60 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19,827.77 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,997.51 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $3,102.01 | 2019-2025 | Korlym |
| Novo Nordisk INC | $2,043.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,083.05 | 2019-2023 | Farxiga |
| Radius Health, INC. | $523.63 | 2019-2025 | Tymlos |
| Abbvie INC. | $487.64 | 2019-2024 | Synthroid, Botox |
| Bayer Healthcare Pharmaceuticals INC. | $264.91 | 2022-2025 | |
| Amgen INC. | $252.14 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $209.01 | 2019-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $189.74 | 2019-2023 | Steglatro |
| Sanofi-Aventis U.S. LLC | $186.02 | 2019-2024 | |
| Recordati_rare_diseases_inc. | $131.14 | 2022-2024 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $125.88 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Medtronic Minimed, INC. | $123.31 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $117.14 | 2021-2025 | Omnipod |
| Currax Pharmaceuticals LLC | $108.98 | 2019-2025 | Contrave |
| Ibsa Pharma INC. | $94.57 | 2019-2020 | |
| Ucb, INC. | $88.91 | 2019 | |
| Celgene Corporation | $86.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.72 | 2019-2020 | |
| Janssen Biotech, INC. | $63.24 | 2019 | |
| Amneal Pharmaceuticals LLC | $57.06 | 2021-2025 | Unithroid |
| Glaxosmithkline, LLC. | $56.11 | 2019 | |
| Medtronic, INC. | $50.23 | 2022-2024 | Minimed 780g |
| Eusa Pharma (US) LLC | $43.56 | 2022 | |
| Beta Bionics, INC. | $41.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $37.64 | 2019-2021 | |
| Pacira Therapeutics, INC. | $30.54 | 2019 | |
| Antares Pharma, INC. | $29.90 | 2024 | Xyosted |
| Soleno Therapeutics, INC. | $28.48 | 2025 | Vykat Xr |
| Madrigal Pharmaceuticals | $26.29 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $26.25 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $25.40 | 2025 | |
| Dexcom, INC. | $24.36 | 2023 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $19.43 | 2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $18.32 | 2019 | |
| Tandem Diabetes Care, INC. | $18.25 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $16.16 | 2025 | |
| Amarin Pharma, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himani Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.